Actively Recruiting
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
Led by Huashan Hospital · Updated on 2024-12-04
120
Participants Needed
1
Research Sites
84 weeks
Total Duration
On this page
Sponsors
H
Huashan Hospital
Lead Sponsor
S
Shanghai Stroke Association
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of Human Urinary Kallidinogenase combined with endovascular therapy in acute ischemic stroke (AIS) patients with large vessel occlusion.
CONDITIONS
Official Title
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant with acute anterior circulation ischemic stroke receiving endovascular treatment within 24 hours (non-bridged).
- Age 18 years or older.
- Modified Rankin Scale score was 0-1 before stroke onset.
- ASPECT score of infarction on emergency CT 7 or higher.
- Emergency CTA showing acute ischemic stroke with large vessel occlusion (internal carotid artery, M1 or M2 segment of middle cerebral artery).
- Emergency CTP or DWI showing infarct core volume between 10 mL and less than 100 mL and low perfusion brain tissue volume to infarct core volume ratio greater than 1.2.
- Willing and able to follow study procedures and sign informed consent (patient or surrogate).
You will not qualify if you...
- Severe heart, liver, or kidney dysfunction, coagulation problems, intolerance to surgery, allergy to Human Urinary Kallidinogenase or contrast agents, or other angiographic contraindications.
- Presence of intracranial hemorrhagic diseases shown by CT or MRI (such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage).
- History of cerebral hemorrhage, brain tumor, brain trauma, or other brain diseases.
- Regular use of ACEI antihypertensive drugs that cannot be stopped.
- Major surgery or severe trauma within the past 2 weeks.
- Poor compliance or inability to fully follow study protocol.
- Pregnancy or breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Huashan Hospital
Shanghai, China, 200040
Actively Recruiting
Research Team
Q
Qiang Dong, M.D.
CONTACT
W
Wenjie Cao, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here